EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
8.48
-0.48 (-5.36%)
Nov 21, 2024, 2:34 PM EST - Market open
EyePoint Pharmaceuticals Revenue
EyePoint Pharmaceuticals had revenue of $10.52M in the quarter ending September 30, 2024, a decrease of -30.77%. This brings the company's revenue in the last twelve months to $45.71M, up 7.50% year-over-year. In the year 2023, EyePoint Pharmaceuticals had annual revenue of $46.02M with 11.14% growth.
Revenue (ttm)
$45.71M
Revenue Growth
+7.50%
P/S Ratio
9.93
Revenue / Employee
$377,793
Employees
121
Market Cap
594.61M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
Dec 31, 2019 | 20.37M | 15.79M | 345.53% |
Dec 31, 2018 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 5.59B |
InnovAge Holding | 786.51M |
Definitive Healthcare | 255.85M |
Entrada Therapeutics | 215.23M |
Butterfly Network | 76.22M |
IRADIMED CORPORATION | 71.31M |
Phathom Pharmaceuticals | 26.27M |
Exscientia | 22.88M |
EYPT News
- 7 days ago - EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity - Seeking Alpha
- 17 days ago - EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 20 days ago - EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - GlobeNewsWire
- 22 days ago - EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - GlobeNewsWire
- 23 days ago - EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 24 days ago - EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema - GlobeNewsWire
- 4 weeks ago - EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration - GlobeNewsWire
- 5 weeks ago - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire